Purpose: contract award for sbir topic 073 phase I "a rapid nucleic acid test for the point of care detection of malaria" in the amount of $299,974.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93019C00026
- Awardee
-
Crosslife Technologies Inc. UEI LFE6DJ6KL4E5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,974
Award facts
- Opportunity
-
- PHS20191 Solicitation number
- Contract value 100% obligated
- $299,974.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 13 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Carlsbad, CA 92010, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Original award | $299,974 |
About this award
The U.S. Department of Health and Human Services, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract in the amount of $299,974 to Crosslife Technologies Inc., a self-certified small disadvantaged business, for a Small Business Innovation Research (SBIR) Phase I project titled "A Rapid Nucleic Acid Test for the Point of Care Detection of Malaria." The contract was set aside for total small businesses and had an award date of August 14, 2019 with a completion date of August 18, 2020. Crosslife Technologies Inc. has previously received SBIR program awards and project grants from NIH agencies such as the National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of Child Health and Human Development for the research, development, and validation of rapid point of care diagnostic tests for infectious diseases that can be used in low resource settings.
Quick answers
Who was awarded contract 75N93019C00026?
75N93019C00026 was awarded to Crosslife Technologies Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 14, 2019.
How much is contract 75N93019C00026 worth?
The government has obligated $299,974 on 75N93019C00026.
Was contract 75N93019C00026 competed?
The extent of competition for 75N93019C00026 was full and open competition after exclusion of sources. The government received 13 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award